Biotechnology Co. Divine Skin, Inc. (DSKX.OB) Introduces First Topical Hair-Growth Treatment with Astressin-B Peptide

MIAMI BEACH, Fla., Sept. 20, 2011 — Divine Skin Inc. (OTC Bulletin Board:DSKX.ob – News) has announced the release of the first topical hair-growth treatment based on astressin-B, a peptide newly discovered to regrow hair on bald mice. Divine Skin becomes the first biotech developer to synthesize and commercialize the peptide for human use in a cosmetic product, to be marketed as Spectral.F7 under the DS Laboratories brand.

“Astressin-B is a very complex peptide that is difficult to synthesize,” said Divine Skin CEO Daniel Khesin. “So we are especially excited that the resulting product will be reasonably priced as well as cutting-edge, considering the extraordinary development schedule and cost.”

Astressin-B sparked extensive media coverage worldwide and excitement around the biotech industry after a clinical study, conducted by the University of California Los Angeles and the Veterans Administration, was published in February. By applying the peptide (a protein fragment) subcutaneously to mice that had gone bald due to overexpression of stress hormones, scientists showed that astressin-B blocked receptors for corticotropin-releasing factor, involved in the stress response, and led to hair regrowth.

[Read more...]